This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AZD-103, scyllo-inositol, D005, ELND005, D5
Description: ELND005 is a small molecule therapeutic agent that acts by disaggregating or preventing the assembly of beta amlyoid fibrils.
Elan and Transition
Elan Corporation and Transition Therapeutics announced in September 2006 an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer's disease.
Under the terms of the agreement, Transition will receive upfront payments of US$15 million: US$7.5 million in 2006 and the remaining US$7.5 million in 2007. In addition, dependant upon the successful development, regulatory approval and commercialization of ELND005, Transition will be eligible to receive milestone payments of up to US$185 million. Elan and Transition will share the costs and operating profits (70%/30%, respectively, with an option for Transition to increase that to 40% or revert to a royalty type arrangement) of ELND005 if successfully developed and commercialized.
In November 2010, Transition Therapeutics announced an amendment to its agreement with Elan for the development and commercialization of ELND005....See full deal structure in Biomedtracker
Partners: Perrigo Company PLC
Additional information available to subscribers only: